We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Breaching the Blood-Brain Barrier

By CLN Stat
Posted on 27 Jun 2018
A late-breaking session at the AACC 70th Annual Scientific Meeting & Clinical Lab Expo in Chicago will highlight the uses and implications of the first chemical biomarker test cleared by the U.S. More...
Food and Drug Administration for detecting mild traumatic brain injury (mTBI) or concussion. It will also examine other TBI biomarkers.

“TBI is a very large problem in both civilian and military occupations and activities,” session moderator Robert Christenson, PhD, professor of pathology and professor of medical and research technology at the University of Maryland School of Medicine in Baltimore, told CLN Stat. “Blood is a simple specimen to obtain, and a biomarker would be of great value for rapid rule-out or rule-in of TBI. This would be from economic and, most importantly, patient health reasons,” said Christenson, who is co-presenting with Frank Peacock, MD, professor of emergency medicine at Baylor College of Medicine in Houston, and Robert Welch, MD, director of clinical research at Wayne State University School of Medicine in Detroit.

In his presentation, Christenson plans to cover the interpretation of brain biomarker tests. The speakers also will describe the characteristics of an ideal TBI marker, as well as the evidence for proposed biomarkers that have already been explored. Another discussion will address the seminal trial of the newly cleared test, called Brain Trauma Indicator (BTI), and detail how BTI might be used in emergency department settings.

Detecting TBI in blood is not without its challenges, Christenson emphasized. A blood-brain barrier exists between the blood compartment and the brain compartment. “To determine what brain-specific biomarkers are of high enough concentration to leak over to the blood compartment and be detected in a reasonable time frame after injury has been challenging. There are both biological and technical measurement considerations,” he said.

Clinical laboratorians from all aspects of testing and reimbursement need to understand the inner workings of brain biomarkers, and in particular what the BTI test is—and what it’s not, Christenson indicated. “Interpretation of the test results will also be critical for laboratorians to know, as they will be asked questions about test results by clinicians,” he added.

Participants of this session will be able to:

1. Identify strategies for identifying, quantifying, and validating potential TBI biomarkers;
2. Discuss the algorithm for interpreting the Brain Trauma Index; and
3. List ways that TBI biomarkers can benefit patients and decrease healthcare costs.

Register now for the AACC 70th Annual Scientific Meeting & Clinical Lab Expo in Chicago to attend this informative session on August 2. Attendees will receive 1.5 CE hours.



Visit AACC 2018 >>



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Compound Management Solution
comPOUND
New
Blood Culture Control Panel
Gram-Negative Blood Culture Control Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.